Literature DB >> 9973474

CD40 activation boosts T cell immunity in vivo by enhancing T cell clonal expansion and delaying peripheral T cell deletion.

J R Maxwell1, J D Campbell, C H Kim, A T Vella.   

Abstract

In this report we show that activation of APC with an agonist anti-CD40 mAb profoundly alters the behavior of CD4 T cells in vivo. Stimulation of mice with anti-CD40 2 days before, but not 1 day after, administration of superantigen (SAg) enhanced CD4 and CD8 T cell clonal expansion by approximately threefold. Further, CD40 activation also delayed peripheral T cell deletion after activation. Dying, activated T cells were quantitated by detecting extracellular phosphatidylserine with concomitant staining for SAg-reactive T cells using a TCR Vbeta-specific mAb. Upon close examination, it was shown that CD40 activation delayed the death of the activated T cells. Additionally, it was found that enhanced survival of CD4 T cells was equally dependent on APC expression of B7-1 and B7-2. This is in contrast to CD8 T cells, which did not depend as much on B7-1 as B7-2. Thus, CD40 activation indirectly promotes T cell growth and delays the death of SAg-stimulated CD4 T cells in vivo. These data suggest that one way CD40 activation promotes a more robust immune response is by indirectly increasing the production of effector T cells and by keeping them alive for longer periods of time.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9973474

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  23 in total

1.  Rescue of CD8 T cell-mediated antimicrobial immunity with a nonspecific inflammatory stimulus.

Authors:  Roman A Tuma; Rielle Giannino; Patrick Guirnalda; Ingrid Leiner; Eric G Pamer
Journal:  J Clin Invest       Date:  2002-11       Impact factor: 14.808

2.  CD45 opposes beta-amyloid peptide-induced microglial activation via inhibition of p44/42 mitogen-activated protein kinase.

Authors:  J Tan; T Town; T Mori; Y Wu; M Saxe; F Crawford; M Mullan
Journal:  J Neurosci       Date:  2000-10-15       Impact factor: 6.167

3.  Co-administration of CD40 agonistic antibody and antigen fails to overcome the induction of oral tolerance.

Authors:  Yeonseok Chung; Dong-Hyeon Kim; Seung-Ho Lee; Chang-Yuil Kang
Journal:  Immunology       Date:  2004-01       Impact factor: 7.397

4.  Effector CD8 T cells possess suppressor function after 4-1BB and Toll-like receptor triggering.

Authors:  Lara Myers; Chikara Takahashi; Robert S Mittler; Robert J Rossi; Anthony T Vella
Journal:  Proc Natl Acad Sci U S A       Date:  2003-04-14       Impact factor: 11.205

5.  Antigen targeting to major histocompatibility complex class II with streptococcal mitogenic exotoxin Z-2 M1, a superantigen-based vaccine carrier.

Authors:  Fiona J Radcliff; Jacelyn M S Loh; Birgit Ha; Diana Schuhbauer; James McCluskey; John D Fraser
Journal:  Clin Vaccine Immunol       Date:  2012-02-01

Review 6.  Osteoblast responses to bacterial pathogens: a previously unappreciated role for bone-forming cells in host defense and disease progression.

Authors:  Ian Marriott
Journal:  Immunol Res       Date:  2004       Impact factor: 2.829

7.  A critical role for protein kinase C-theta-mediated T cell survival in cardiac allograft rejection.

Authors:  Santhakumar Manicassamy; Dengping Yin; Zheng Zhang; Luciana L Molinero; Marisa-Luisa Alegre; Zuoming Sun
Journal:  J Immunol       Date:  2008-07-01       Impact factor: 5.422

8.  Induction of immune tolerance to FIX by intramuscular AAV gene transfer is independent of the activation status of dendritic cells.

Authors:  Arpita S Bharadwaj; Meagan Kelly; Dongsoo Kim; Hengjun Chao
Journal:  Blood       Date:  2009-11-17       Impact factor: 22.113

9.  Primary and malignant cholangiocytes undergo CD40 mediated Fas dependent apoptosis, but are insensitive to direct activation with exogenous Fas ligand.

Authors:  Elizabeth H Humphreys; Kevin T Williams; David H Adams; Simon C Afford
Journal:  PLoS One       Date:  2010-11-17       Impact factor: 3.240

10.  Lipopolysaccharide potentiates effector T cell accumulation into nonlymphoid tissues through TRIF.

Authors:  Jeremy P McAleer; Robert J Rossi; Anthony T Vella
Journal:  J Immunol       Date:  2009-05-01       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.